DoW, Ovarian Cancer, Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award
About
Summary: Created in FY23, the Ovarian Cancer Clinical Trial Academy (OCCTA) supports the next generation of Early-Career Investigators (ECIs) in clinical trial research to produce effective treatments and cures for ovarian cancer. The OCCTA, through its Leadership, provides for professional and leadership development of the ECIs to include skills and competencies needed to execute clinical trials, providing intensive mentoring, national networking, collaborations, and a peer group for junior clinical trialists. The OCCTA will bring together established investigators (the Academy Dean and Assistant Dean), established Career Guides (mentors), and a group of ECIs/Scholars to conduct successful, highly productive clinical trials in ovarian cancer. Distinctive Features: Research funded under this FY26 funding opportunity will support translational research and small-scale, early-phase clinical trials in ovarian cancer. Preliminary data are required, however, these data do not necessarily need to be derived from the ovarian cancer research field. The ECI must be within 12 years of their last postdoctoral research position (Ph. D.), clinical fellowship (M. D.), or equivalent at the time of full application submission deadline. The ECI must commit no less than 25% effort to this award and/or OCCTA activities for the first two years. The Designated Mentor must be a clinical trialist with a strong record of mentoring and training early-career investigators.
The DoW Ovarian Cancer Clinical Trial Academy (OCCTA) Early-Career Investigator Award is designed to support the next generation of clinical trial researchers committed to advancing ovarian cancer treatment and cures. This FY26 funding opportunity is ideal for early-career investigators (ECIs) within 12 years of completing their postdoctoral research position, clinical fellowship, or equivalent who are passionate about translational research and early-phase clinical trials in ovarian cancer. The award provides more than just funding—it offers a comprehensive professional development program featuring intensive mentoring from established clinical trialists, national networking opportunities, peer collaboration with fellow junior researchers, and leadership training. ECIs must commit at least 25% effort to the award and OCCTA activities for the first two years. This program is particularly valuable for researchers seeking to build their independent research careers while contributing to breakthrough ovarian cancer therapies. Preliminary data are required but do not need to originate from ovarian cancer research. Applicants benefit from structured mentorship, evidence-based clinical trial execution skills, and access to an established network of leading investigators. For current funding amounts, specific eligibility requirements, and detailed application procedures, visit the official Department of Defense or sponsoring agency website.
Funding Facts
● Applications openDeadline
October 1, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Amount varies by cycle—consult official website for FY26 details
Deadline
2026-10-01
Grant Type
federal
Application Cycle
Annual (FY26 deadline: October 1, 2026)
Best For
Early-career clinical investigators in translational research and early-phase ovarian cancer clinical trials
Frequently Asked Questions
Who is eligible for DoW, Ovarian Cancer, Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award?
Early-Career Investigators (ECIs) within 12 years of completing their last postdoctoral research position (Ph.D.), clinical fellowship (M.D.), or equivalent at the time of full application submission are eligible. Applicants must be able to commit at least 25% effort to the award and OCCTA activities for the first two years. A Designated Mentor who is an experienced clinical trialist with a strong mentoring record must be identified. For complete eligibility criteria and any additional requirements, consult the official funding announcement on the Department of Defense grants website.
How much funding does DoW, Ovarian Cancer, Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award provide?
The specific funding amounts for this FY26 opportunity have not been publicly detailed in available summaries. Funding may vary by cycle and award tier. To learn about current funding ranges and maximum award amounts, please visit the official Department of Defense or DoD-supported grant management portal for the most up-to-date financial information.
How do I apply for DoW, Ovarian Cancer, Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award?
Applications are submitted through the official Department of Defense grants portal or designated submission system. The FY26 deadline is October 1, 2026. Applicants should prepare a comprehensive proposal including preliminary data, a detailed research plan for translational or early-phase clinical trials, mentorship agreements, and evidence of institutional support. For detailed application instructions, required forms, submission procedures, and technical guidance, visit the official DoD grants website or contact the program officer directly.
What can DoW, Ovarian Cancer, Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award funding be used for?
This award supports translational research and small-scale, early-phase clinical trials focused on ovarian cancer. Funding enables ECIs to conduct rigorous clinical trial research while participating in professional development, mentorship, and leadership training through the OCCTA program. Researchers can use support for research operations, clinical trial execution, and their dedicated effort toward the award. For specific allowable costs and budget guidelines, consult the official funding announcement or the sponsoring agency's cost policies.
Last updated: July 5, 2026